Merck KGaA, Pfizer drug fails late-stage cancer trial

Merck KGaA and Pfizer announced that the cancer immunotherapy avelumab did not meet the primary endpoints of a phase 3 ovarian cancer trial.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news